Three posters to be presented featuring pre-clinical data of potential best-in-class FGFR3 selective inhibitor, SMARCA2 selective inhibitor, and P53 Y220C reactivatorCandidates for FGFR3 and SMARCA2 ...

Co-led by Forbion and Sofinnova Partners, along with founding investor Monograph Capital, and WeatherdenInnovative lead program, ELV001, in-licensed by Elevara from Japan’s Teijin Pharma with good ...

Objective Peer mentoring has been shown to be an effective intervention for chronic conditions with evidence to suggest that ...

With $70 million and a phase 2 ready asset in hand, British biotech Elevara Medicines has emerged to try to revolutionize the ...

LEO Pharma A/S, a global leader in medical dermatology, is advancing the understanding of skin disease and its impact on ...

Background Data on cardiorespiratory fitness (CRF) in psoriatic arthritis (PsA) are scarce. This study aimed to determine the ...

I am a healthy 69-year-old female. I walk every day and belong to an exercise group that I attend twice a week. I’m writing ...

Recovering from a drug addiction isn't a question of willpower. That's something Kari Bradley, a 53-year-old licensed behavioral peer support specialist, wished she knew 20 years ago. At Cedar Creek ...

This Breast Cancer Awareness Month, let’s pledge to stay informed, perform regular self-checks, encourage screenings, and ...

At 24/7 Wall St., we have closely followed dividend-paying stocks for over 15 years. With a growing audience of savvy Baby ...

YUFLYMA® (adalimumab-aaty), and its unbranded version, are now approved for two additional pediatric indications - adolescent hidradenitis suppurativa (HS) and ...

Modern lifestyles are fueling a surge in fatty liver disease, a condition where excess fat accumulates in the liver. Early ...